Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL
This trial is active, not recruiting.
|Conditions||genital infection viral, human papilloma virus|
|Start date||December 2013|
|End date||December 2015|
|Trial size||220 participants|
|Trial identifier||NCT01957878, PC10VAC02|
Human Papillomavirus (HPV) 16 and HPV 18 (the two virus genotypes targeted by the ProCervix vaccine) are the most common HPV genotypes associated with at least 70% of squamous cell carcinomas and 82% of adenocarcinomas of the cervix The strategy of therapeutic vaccination with ProCervix is to activate and enhance the patient's cellular immune response to HPV . The therapeutic vaccine will be used for women infected by HPV 16, HPV 18, or both. The vaccine targets these HPV infected women with normal or mild cervical cellular dyskaryosis as detectable infections with oncogenic potential.
This will be a double-blind, randomised, placebo-controlled, parallel group study assessing the efficacy of ProCervix or placebo (concomitantly administered with imiquimod cream).
ProCervix will be delivered with a topical agent, imiquimod, applied to the injection sites as a vaccine adjuvant.
The population proposed for this study represents an otherwise healthy female population who are infected with HPV 16 and/or HPV 18. The safety and tolerability of this therapeutic vaccine has been shown in the ongoing Phase I study, and the proposed population may in theory derive benefit from this vaccine.
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
|Tienen, Belgium||Regionaal Ziekenhuis Heilig Hart Tienen Hospital||no longer recruiting|
|Antwerp, Belgium||Centre for the Evaluation of Vaccination Vaccine & Infectious Disease Institute (VAXINFECTIO) Faculty of Medicine University of Antwerp Belgium||no longer recruiting|
|Charleroi, Belgium||Grand Hôpital de Charleroi Site Notre-Dame||no longer recruiting|
|Leuven, Belgium||University Hospitals Leuven||no longer recruiting|
|Helsinki, Finland||Helsinki University Central Hospital||no longer recruiting|
|Kuopio, Finland||Kuopio University Hospital||no longer recruiting|
|Tampere, Finland||Tampereen yliopistollinen sairaala Hospital||no longer recruiting|
|Amiens, France||CHU Amiens Hopital Sud||no longer recruiting|
|Besançon, France||Hôpital Saint Jacques||no longer recruiting|
|Clermont-Ferrand, France||GORH, CHU Estaing||no longer recruiting|
|Dijon, France||CHU Dijon||no longer recruiting|
|Lille, France||Hôpital Jeanne de Flandre CHU de Lille||no longer recruiting|
|Nîmes, France||CHU de Nîmes - Hopital Universitaire Caremeau||no longer recruiting|
|Paris, France||Centre d'Investigation Clinique de Vaccinologie Cochin Pasteur (CIC BT505)||no longer recruiting|
|Pierre Benite, France||Centre Hospitalier Lyon Sud||no longer recruiting|
|Reims, France||CHU de Reims Institut Alix de Champagne||no longer recruiting|
|Strasbourg, France||Hôpital de Hautepierre||no longer recruiting|
|Berlin, Germany||Charité - Universitätsmedizin Berlin Hospital||no longer recruiting|
|Erlangen, Germany||Universitätsklinikum Erlangen Hospital||no longer recruiting|
|Essen, Germany||Elisabeth Krankenhaus Essen GmbH - Clinic/Outpatient Facility||no longer recruiting|
|Jena, Germany||Klinikum der Friedrich Schiller Universität Jena Hospital||no longer recruiting|
|München, Germany||LMU Klinikum der Universität- Hospital||no longer recruiting|
|Wolfsburg, Germany||Klinikum Wolfsburg Hospital||no longer recruiting|
|Amsterdam, Netherlands||Center Gynaecological Oncology Amsterdam AMC, NKI-AVL, VUmc||no longer recruiting|
|Nieuwegein, Netherlands||St. Antonius Ziekenhuis Hospital||no longer recruiting|
|Barcelona, Spain||Hospital Clinic Dept of Obstetrics and Gynecology C/ Villarroel Unidad de Ginecología Oncológica, Instituto Clínico de Ginecología y Obstetricia y Neonatología (ICGON), Hospital Clínic, Instituto de Investigaciones Biomédi||no longer recruiting|
|Barcelona, Spain||Hospital del Mar||no longer recruiting|
|Barcelona, Spain||Hospital Universitari Vall D Hebron||no longer recruiting|
|Barcelona, Spain||Institut Catala d'Oncologia L'Hopitalet de Llobregat||no longer recruiting|
|Lugo, Spain||Clinica Ginecologica Ceoga, Clinic/Outpatient Facility||no longer recruiting|
|Madrid, Spain||Hospital Clínico San Carlos||no longer recruiting|
|Madrid, Spain||Hospital La Paz de Madrid||no longer recruiting|
|Madrid, Spain||Hospital Universitario "12 de Octubre"||no longer recruiting|
|Malaga, Spain||Hospital Regional Universitario Carlos Haya - Hospital Materno Infantil||no longer recruiting|
|Sevilla, Spain||Hospital Sagrado Corazón de Sevilla||no longer recruiting|
|Dumfries, United Kingdom||Dumfries and Galloway Royal Infirmary Hospital||no longer recruiting|
|Liverpool, United Kingdom||Liverpool - GUM - Liverpool Centre for Sexual Health||no longer recruiting|
|London, United Kingdom||St Mary's Hospital||no longer recruiting|
|Manchester, United Kingdom||Academic O&G University of Manchester Research - St Mary's Hospital||no longer recruiting|
|York, United Kingdom||The Centre for Immunology and Infection Hull York Medical School University of York||no longer recruiting|
|Endpoint classification||efficacy study|
|Intervention model||parallel assignment|
|Masking||double blind (subject, caregiver, investigator, outcomes assessor)|
Clearance of HPV 16 and HPV 18 infection at Month 12 using a type specific, sensitive and quantitative HPV PCR assay.
time frame: month 12
Clearance of HPV 16 and HPV 18 infection.
time frame: Month 6, 15, 18, 24
Female participants from 25 years up to 50 years old.
Inclusion Criteria: - A subject will be eligible for inclusion in this study if the following criteria apply: 1. Subject is female between the ages of 25 and 50 years (inclusive). 2. Subject is pre-menopausal . 3. Subject must have cervical HPV 16 and/or 18 infection confirmed by RT-PCR 4. Subject has a cervical cytological evaluation with a normal, ASCUS or LSIL result at baseline. 5. Subject has employed highly effective contraception the month prior to the first vaccination and will agree to employ highly effective contraception for at least 12 months after the first vaccination. . 6. Subject is in general good health based on medical history and physical examination. 7. Subject is able to communicate effectively with study personnel and is considered reliable, willing, and cooperative in terms of compliance with the protocol requirements. 8. Subject voluntarily gives written informed consent to participate in the study. Exclusion Criteria: 1. Subject has a current acute or chronic disease, other than infection with HPV, which would be expected to interfere with the planned evaluations of response 2. Subject has vaginal atrophy with or without topical hormonal therapies or systemic selective estrogen receptor modulators (SERMs). 3. Subject has prior exposure to HPV prophylactic vaccine or subject has participated in the past in another vaccination clinical trial related to infection with HPV 4. Current high grade lesions or history of untreated high grade cervical lesion (either CIN2 or CIN3). 5. Subject has current or a history of cancer of the cervix. 6. Subject has clinically significant (CS) gynaecological abnormalities that could interfere with study evaluation, in the judgment of the Investigator (e.g. prolapse, myoma, fibroid, hysterectomy). 7. Subject has a laboratory abnormality Grade ≥ 2, as defined using the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vaccine Clinical Trials, 8. Subject has received any live viral vaccine within 3 months or any other non live vaccine within 2 weeks of first study product administration. 9. Subject has primary or secondary systemic immunosuppression 10. Subject has a history of severe allergy (requiring hospital care) or history of severe asthma 11. Subject has a history of malignant cancer, except the following adequately treated cancers: basal cell carcinoma, or dermatological squamous cell carcinoma. 12. Subject was administered with another investigational drug or vaccine within 30 days prior to the screening visit or is participating in any other study. 13. Subject has a known hypersensitivity to imiquimod. 14. Subject has a history of severe reaction to any drug or vaccination. 15. Subject has a medical condition with clinical and/or biological consequences judged by the Investigator incompatible with vaccination(s). 16. Subject has positive results for human immunodeficiency virus (HIV), hepatitis B virus (HBV) surface antigen (HBsAg), or hepatitis C virus (HCV). 17. Subject has a symptomatic vaginal or genital infection 18. Subject has a history of or currently active genital herpes disease. 19. Subject is pregnant or is breastfeeding. 20. Subject has a positive serum human chorionic gonadotrophin (HCG) result at enrolment.
|Official title||A Double-blind, Randomised, Placebo-controlled, Phase II Study to Evaluate ProCervix Efficacy to Clear HPV 16 and HPV 18 Infection in Women With Normal Cytology or ASCUS/LSIL|
Call for more information